ribavirin has been researched along with narlaprevir in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Boonstra, A; de Bruijne, J; de Knegt, RJ; Hotho, DM; Janssen, HL; Reesink, HW; Spaan, M; Treitel, MA | 1 |
| Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, E; Janssen, HL; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Thomas, XV; Treitel, MA; Weegink, CJ | 1 |
| Gapon, MN; Grushko, IP; Romanova, EB; Tverdokhlebova, TI; Vodyanitskaya, SY | 1 |
2 trial(s) available for ribavirin and narlaprevir
| Article | Year |
|---|---|
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfones; Treatment Outcome; Urea; Viral Load | 2013 |
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
Topics: Adult; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Evolution, Molecular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sulfones; Urea; Viral Load; Viral Nonstructural Proteins | 2013 |
2 other study(ies) available for ribavirin and narlaprevir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[Comparative evaluation of the effectiveness of narlaprevir in the composition of interferon and interferon-free treatment regimens for patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Ritonavir; Treatment Outcome | 2022 |